The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction and b) as a second component cytarabine as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.本發明係關於一種醫藥產物,其包括a)作為第一組份之MDM2-p53相互作用抑制劑;及b)作為第二組份之阿糖胞苷(cytarabine);該醫藥產物作為組合製劑用以依序或同時用於治療癌症、尤其是AML。
